Master of Biological Engineering and Master of Business Administration

With over a decade of experience in the biologics industry, particularly in antibody and cell-based therapies, he specializes in process development and commercial production. He has been involved in the process development and commercialization of China's first adalimumab biosimilar, the global bevacizumab biosimilar, and the technology transfer of tocilizumab biosimilar to multinational corporations (MNCs), and the process development for pivotal trials of China's first cell and gene therapy product. His expertise covers the design and operation of various types of facilities, including hybrid, single-use, and stainless-steel systems, from conceptual design to commissioning and the renovation of multiple facilities.